Attached files
| file | filename |
|---|---|
| 8-K - Emmaus Life Sciences, Inc. | v164529_8k.htm |
| EX-99.2 - Emmaus Life Sciences, Inc. | v164529_ex99-2.htm |
| EX-99.3 - Emmaus Life Sciences, Inc. | v164529_ex99-3.htm |
|
|
Investor
Relations:
Marty
Tullio, Managing Partner
McCloud
Communications, LLC
949.553.9748
marty@mccloudcommunications.com
|
 |
|
Media
Relations:
|
|
|
Jon
Steinman
|
Jennifer
Simpson
|
|
202-270-9240
|
202-569-9180
|
|
jsteinman@washingtonmedia.com
|
jsimpson@washingtonmedia.com
|
Breakthrough
Results in Depression Care Announced by CNS Response at the U.S. Psychiatric and
Mental Health Congress
Patients
Using rEEG® -Guided Treatment
Had Considerably Better Outcomes
with
Statistical Significance “Exceeding Expectations”
Costa
Mesa, CA – November 3, 2009 – CNS
Response, Inc. (OTCBB: CNSO) reported the results of a landmark study
presented by Charles DeBattista, D.M.H, M.D., at the U.S. Psychiatric and Mental
Health Congress. The poster presentation, titled Referenced-EEG® (rEEG)
Efficacy Compared to
STAR*D For Patients With Depression Treatment Failure: First Look At Final
Results, highlighted a dramatic improvement in personalized
medicine technology for use in treatment of patients with depression. In this
study, rEEG proved effective at predicting medication response for
treatment-resistant patients approximately 65 percent of the time.
The study
included 114 patients in 12 medical centers, including Harvard, Stanford,
Cornell, UCI and Rush. The 12-week study found that rEEG significantly
outperformed the modified STAR*D treatment algorithm. The difference, or
separation, between rEEG and the control group was 50 and 100 percent for the
study’s two primary endpoints. Typically, separation between a new treatment and
a control group is about 10 percent in antidepressant studies.
“These
outcomes are consistent with previous rEEG studies, which included three
prospective, controlled trials and eight case series, but the robustness and
statistical significance of these results exceeded our expectations,” said CNS
president and chief medical officer Daniel Hoffman, M.D.
“Psychiatry
has lacked useful laboratory tests to select medications for treatment-resistant
depressed patients. While needing further study, this trial is one of the larger
ones to demonstrate that there may be a role for technology that assists
physicians in selecting better treatment options for their patients,” said Dr.
Charles DeBattista, an award-winning doctor at Stanford University Medical
Center, who helped lead the study on rEEG.
Depression
costs U.S. employers $83 billion annually, with treatment-resistant depression
accounting for over half of that cost. On average, these patients cost $8,500
more per year than patients with ordinary depression. rEEG is the first
objective, physiology-based, personalized medical technology consistently shown
to guide psychiatrists to appropriate treatment for the most challenging
patients.
- more
-
Breakthrough
Results in Depression Care Announced by CNS Response at the U.S. Psychiatric and
Mental Health Congress
Page
2
The CNS
Response study, the largest in the company’s history, was a randomized, blinded,
controlled, parallel group, multicenter study. The patients in the study
experienced depression treatment failure of one of more SSRIs and/or had failure
with at least two classes of antidepressants. The patients fell into two groups:
1) those treated with rEEG medication guidance, and 2) those treated with the
modified STAR*D treatment algorithm.
“This is
the promise of personalized medicine, tailoring therapies to the unique
medication response profile of each individual patient,” said George Carpenter,
chief executive officer of CNS Response, Inc., which developed the patented
technology. “Those suffering from the most resistant forms of depression will
now have an effective treatment option, and doctors will no longer have to play
an extended and costly guessing game to see what works best.”
About
CNS Response
Today,
most physicians are able to base treatment on objective test data, such as EKGs,
MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to
those physicians practicing psychiatry.
CNS
Response has developed a patented data-analysis capability that, with the help
of a simple, non-invasive EEG, will analyze a patient’s brain waves and compare
the results to an extensive patient outcomes database. The process produces a
rEEG® report providing a psychiatrist with guidance to personalize medication
regimens for a patient, based on the patient's own brain physiology. To read
more about the benefits this patented technology provides physicians, patients
and insurers, please visit the CNS Response website,
www.cnsresponse.com.
Safe
Harbor Statement under the Private Securities Litigation Reform Act of
1995
Except for the historical information
contained herein, the matters discussed are forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the
Company's filings with the Securities and Exchange Commission. These risks and
uncertainties could cause actual results to differ materially from any
forward-looking statements made herein.
# #
#